News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
News Alamar, Hemab, Kailera, and Seaport advance IPOs The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.
News Electra banks $183m for sHLH drug, and other biofinancings Our round-up of recent biotech financings includes a big round for Electra, with Hemab, Zag Bio, Elevara, Expedition, and Curve also adding new funds.
News uniQure sets course to US filing for Huntington gene therapy Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
